Desitin

Request correction

Product brand

Unclaimed

A U.S. baby-care brand best known for zinc-oxide products that help treat and prevent diaper rash.

Last updated October 14, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

Desitin is an American over-the-counter baby-care brand centered on diaper-rash treatment and prevention. Its best-known products are zinc-oxide creams and pastes applied as protective barriers to irritated or vulnerable skin in the diaper area. The brand is primarily associated with infant and young-child care, although its topical products are also marketed for broader skin-protection uses depending on the formulation and labeling. The Desitin trademark has commercial roots going back to the 1920s. U.S. trademark records identify first use in commerce in 1926, while the mark was registered in 1951. The brand's earlier positioning covered a broader medical ointment category, including applications for wounds, abrasions, chapped skin, irritation, and other dermatological conditions. Over time, Desitin became strongly identified with pediatric skin care and diaper dermatitis, a category in which barrier products containing zinc oxide are widely used. Desitin's modern brand architecture is built around different levels of protection and treatment intensity. Daily Defense Cream contains 13% zinc oxide and is positioned for routine prevention or use at the first signs of irritation. Maximum Strength Original Zinc Oxide Paste contains 40% zinc oxide and is positioned for more severe or persistent diaper rash. The brand also markets a Multipurpose Ointment intended for broader skin-protection applications. Product availability and naming can vary by market and over time. The brand was owned by Pfizer before Johnson & Johnson acquired Pfizer's consumer-health business in 2006. The transaction required regulatory remedies because the Federal Trade Commission viewed Pfizer's Desitin and Johnson & Johnson's Balmex as significant competitors in the U.S. over-the-counter diaper-rash market. Unlike Balmex, Desitin remained with the combined consumer-health business. Johnson & Johnson subsequently transferred its consumer-health portfolio into Kenvue, which became an independent publicly traded company in 2023. Desitin is now part of Kenvue's Essential Health portfolio. Desitin's positioning emphasizes practical, familiar, and accessible everyday care rather than premium beauty or highly specialized dermatology. Its visual and commercial identity has historically relied on strong product differentiation by color and strength, straightforward usage guidance, and parent-oriented education about prevention, treatment, and skin-barrier protection. The brand's current U.S. website presents a portfolio organized around treating and protecting a baby's bottom, supported by educational information about diaper-rash care and product selection. The brand is most strongly established in the United States. Public information supports its ownership and U.S. commercial presence, but does not establish a separate global corporate headquarters or a complete list of all countries in which Desitin products are sold. Desitin should therefore be treated as a U.S.-centered product brand within Kenvue's international consumer-health portfolio rather than as a standalone company.

History

Desitin is a U.S. topical-care brand whose identity developed from a broader medicinal ointment business into a specialized diaper-rash franchise. U.S. trademark records list first use in commerce in 1926, making the brand a long-established participant in American over-the-counter skin care. The trademark was registered in 1951 under Desitin Chemical Co. and later passed through Pfizer before becoming part of Johnson & Johnson's consumer-health portfolio. Early trademark descriptions associated Desitin with a medical compound sold as an ointment, powder, or suppository for a broad range of skin and irritation-related applications. These descriptions included wounds, abrasions, chapped skin, burns, dermatitis, and other forms of external irritation. This historical scope was wider than the brand's current public identity, which is concentrated on baby skin protection and diaper dermatitis. The brand's strongest long-term association emerged from the use of zinc oxide as a physical barrier. In diaper care, barrier products are used to help shield skin from moisture and irritants. Desitin's consumer proposition became increasingly straightforward: provide parents and caregivers with a recognizable topical product for preventing or treating diaper rash. The brand's category language has typically emphasized protection, soothing, and support for the baby's skin barrier rather than cosmetic skin enhancement. By the time Pfizer owned Desitin, the brand had become a leading U.S. diaper-rash treatment line. In 2006, Johnson & Johnson proposed to acquire Pfizer's consumer-health business in a transaction valued at approximately $16.6 billion. The FTC concluded that the transaction raised competitive concerns in several over-the-counter categories. In diaper-rash treatments, Pfizer's Desitin and Johnson & Johnson's Balmex were identified as major competing products. To resolve the concern, Johnson & Johnson agreed to divest Balmex to Chattem. Desitin was retained and joined Johnson & Johnson's consumer-health portfolio. The acquisition connected Desitin to a much larger group of consumer-health brands, but the brand itself remained focused on diaper-rash care. Over subsequent years, its product range was organized around different zinc-oxide strengths and use occasions. Daily or routine-use products were designed for prevention and early irritation, while Maximum Strength products were formulated with a higher concentration of zinc oxide for more pronounced rash conditions. The brand also developed multipurpose positioning for selected ointment products. In the 2020s, Johnson & Johnson prepared to separate its consumer-health operations into a new company. Kenvue became an independent publicly traded company in 2023, taking ownership or operating responsibility for a portfolio that included Desitin. Kenvue subsequently established its global headquarters in Summit, New Jersey. The current Desitin website is operated under Kenvue Brands LLC or an affiliated company and is directed toward U.S. consumers. Desitin's present identity combines heritage with highly practical product segmentation. Its consumer communications explain the difference between routine defense and maximum-strength treatment, identify zinc oxide as the central active ingredient, and encourage caregivers to use barrier products as part of regular diaper care. The current U.S. portfolio includes Daily Defense Cream, Maximum Strength Original Zinc Oxide Paste, and Multipurpose Ointment. The brand also maintains educational content covering prevention, treatment, application, storage, and when caregivers should seek additional medical advice. Publicly documented information does not establish a standalone Desitin corporation, a named founder, or an independent Desitin headquarters. The brand is best understood as an active product trademark within Kenvue's Essential Health and baby-care portfolio. Its historical importance comes from its longevity, its role in the development of the U.S. diaper-rash category, and its continuity through ownership changes from Desitin Chemical Co. to Pfizer, Johnson & Johnson, and Kenvue.

2026
Rapid Relief renamed Daily Defense
[2]Desitin contact and FAQ pagedesitin.com
The Desitin FAQ stated that the Rapid Relief product had been renamed Daily Defense and remained intended for routine use at diaper changes.
2024
Kenvue established its Summit, New Jersey headquarters
[9]Kenvue global headquarters announcementkenvue.com
Kenvue identified 1 Kenvue Way in Summit, New Jersey as its new corporate address and global headquarters location.
2023
Desitin transferred to independent Kenvue
[8]Johnson & Johnson consumer-products ownership noticejnj.com
Kenvue became an independent publicly traded company following the separation of Johnson & Johnson's consumer-health business, with Desitin included in the transferred brand portfolio.
2007
FTC consent order finalized
[5]FTC matter: Johnson & Johnson and Pfizerftc.gov
The FTC finalized remedies addressing competition concerns in over-the-counter diaper-rash treatments and other consumer-health categories. Balmex was divested to Chattem, while Desitin remained with Johnson & Johnson.
2006
Pfizer consumer-health acquisition announced
[5]FTC matter: Johnson & Johnson and Pfizerftc.gov
Johnson & Johnson agreed to acquire Pfizer's consumer-health business, bringing Desitin into the Johnson & Johnson consumer portfolio subject to regulatory remedies.
1951
Desitin trademark registered in the United States
[7]Desitin U.S. trademark recordtrademarks.justia.com
The DESITIN word mark was registered in the United States on August 28, 1951.
1926
First use in U.S. commerce
[7]Desitin U.S. trademark recordtrademarks.justia.com
U.S. trademark records identify March 19, 1926 as the first-use date in commerce for the Desitin mark.

Products and positioning

An accessible, practical baby-skincare brand centered on protective zinc-oxide diaper-rash products for infants, young children, and caregivers.

Diaper-rash prevention cream
Desitin Daily Defense Cream
A routine-use diaper-rash cream containing 13% zinc oxide. Desitin positions Daily Defense for use at every diaper change, for prevention, or at the first sign of redness and irritation. It represents the lower-strength, everyday-protection tier of the current U.S. portfolio and was previously marketed under the Rapid Relief name.
Diaper-rash treatment paste
Desitin Maximum Strength Original Zinc Oxide Paste
A concentrated zinc-oxide paste containing 40% zinc oxide, described by the brand as its maximum-strength diaper-rash formulation. It is positioned for more severe or persistent diaper rash and as a heavier protective barrier than the routine-use Daily Defense product. The formulation is sold as an over-the-counter topical product in the United States.
Multipurpose skin-protection ointment
Desitin Multipurpose Ointment
A protective ointment marketed for diaper-area care and other skin-protection applications identified on the product labeling. It broadens the Desitin range beyond a single diaper-rash use case while retaining the brand's practical barrier-care positioning. Exact ingredients and permitted uses depend on the current package labeling.

Marketing campaigns

A Tube for Every Tush
United States
A current Desitin website platform that presents the brand's range as a product choice for different diaper-care needs, including daily protection, multipurpose ointment use, and maximum-strength treatment.
Source
Treating and Preventing Diaper Rash Education
United States
An educational content program explaining diaper-rash prevention, barrier care, application practices, and the distinction between routine and stronger zinc-oxide products.
Source

Brand decisions

2026
Rename Rapid Relief as Daily DefenseOther
Background
Desitin's current FAQ describes a naming change for its routine-use product.
Action taken
The product previously called Rapid Relief was renamed Daily Defense, with the brand continuing to describe it as suitable for use at every diaper change.
Aftermath
The change sharpened the distinction between the everyday-prevention product and the higher-strength Maximum Strength product.
Source
2023
Transfer Desitin to KenvueStrategy
Background
Johnson & Johnson separated its consumer-health activities into Kenvue, an independent consumer-health company.
Action taken
Desitin became part of Kenvue's portfolio of consumer-health brands and was organized within the company's Essential Health activities.
Aftermath
The Desitin brand continued operating under Kenvue ownership and remained focused on U.S. diaper-rash care.
Source
2006
Retain Desitin while divesting BalmexM&A
Background
Johnson & Johnson's proposed acquisition of Pfizer's consumer-health business combined Pfizer's Desitin with Johnson & Johnson's Balmex, two important brands in the U.S. diaper-rash category.
Action taken
To address the FTC's competition concerns, the parties agreed to divest Balmex to Chattem. Desitin remained in the acquired Pfizer consumer-health portfolio.
Aftermath
Desitin continued under Johnson & Johnson's consumer-health organization and later transferred to Kenvue.
Source

Sources9 sources

Cite this profile: Cite the canonical profile. /brand-wiki/desitin · Editorial policy · How profiles are compiled